Key Points
-
Parathyroid hormone (PTH)/parathyroid hormone-related protein (PTHrP) receptor (PTHR1) mediates the biological actions of two endogenous ligands, PTH and PTHrP and has key roles in regulating blood calcium levels and tissue development
-
PTH and PTHrP interact with PTHR1 through similar, although not identical mechanisms, and preferentially stabilize distinct receptor conformations
-
Certain structurally distinct PTH and PTHrP ligand analogues, which stabilize distinct receptor conformations, induce altered signalling responses that differ in signal type and duration
-
Prolonged signalling by certain PTH ligand analogues correlates temporally with ligand–receptor complexes located in endosomes, which suggests mechanisms of signal generation and termination distinct from those described by traditional G-protein-coupled receptor models
-
Consideration of ligand-based mechanisms that control signal duration provide insight into the processes of receptor dysfunction, as wells as guidance for addressing PTHR1-related diseases
-
Identification and incorporation of specific structural features that promote or prevent long-lasting biological responses hold promise for the design of treatments for hypoparathyroidism and osteoporosis, respectively
Abstract
Parathyroid hormone/parathyroid hormone-related protein receptor (PTH/PTHrP type 1 receptor; commonly known as PTHR1) is a family B G-protein-coupled receptor (GPCR) that regulates skeletal development, bone turnover and mineral ion homeostasis. PTHR1 transduces stimuli from PTH and PTHrP into the interior of target cells to promote diverse biochemical responses. Evaluation of the signalling properties of structurally modified PTHR1 ligands has helped to elucidate determinants of receptor function and mechanisms of downstream cellular and physiological responses. Analysis of PTHR1 responses induced by structurally modified ligands suggests that PTHR1 can continue to signal through a G-protein-mediated pathway within endosomes. Such findings challenge the longstanding paradigm in GPCR biology that the receptor is transiently activated at the cell membrane, followed by rapid deactivation and receptor internalization. Evaluation of structurally modified PTHR1 ligands has further led to the identification of ligand analogues that differ from PTH or PTHrP in the type, strength and duration of responses induced at the receptor, cellular and organism levels. These modified ligands, and the biochemical principles revealed through their use, might facilitate an improved understanding of PTHR1 function in vivo and enable the treatment of disorders resulting from defects in PTHR1 signalling. This Review discusses current understanding of PTHR1 modes of action and how these findings might be applied in future therapeutic agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Urena, P. et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133, 617–623 (1993).
Vilardaga, J. P., Romero, G., Friedman, P. A. & Gardella, T. J. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell. Mol. Life Sci. 68, 1–13 (2011).
Kousteni, S. & Bilezikian, J. P. The cell biology of parathyroid hormone in osteoblasts. Curr. Osteoporos. Rep. 6, 72–76 (2008).
Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434–1446 (2007).
Blaine, J., Chonchol, M. & Levi, M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin. J. Am. Soc. Nephrol. 10, 1257–1272 (2015).
Tawfeek, H. A., Qian, F. & Abou-Samra, A. B. Phosphorylation of the receptor for PTH and PTHrP is required for internalization and regulates receptor signaling. Mol. Endocrinol. 16, 1–13 (2002).
Lohse, M. J. Molecular mechanisms of membrane-receptor desensitization. Biochim. Biophys. Acta 1179, 171–188 (1993).
Brown, E. M. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. 71, 371–411 (1991).
Habener, J. F., Rosenblatt, M. & Potts, J. T. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol. Rev. 64, 985–1053 (1984).
Cupp, M. E., Nayak, S. K., Adem, A. S. & Thomsen, W. J. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways. J. Pharmacol. Exp. Ther. 345, 404–418 (2013).
Dean, T. et al. Mechanisms of ligand binding to the PTH/PTHrP receptor: selectivity of a modified PTH(1–15) radioligand for GαS-coupled receptor conformations. Mol. Endocrinol. 20, 931–942 (2006).
Horwitz, M. J. et al. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1–36) [HPTHrP-(1–36)] versus HPTH-(1–34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J. Clin. Endocrinol. Metab. 88, 1603–1609 (2003).
Abousamra, A. B. et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc. Natl Acad. Sci. USA 89, 2732–2736 (1992).
Singh, A. T., Gilchrist, A., Voyno-Yasenetskaya, T., Radeff-Huang, J. M. & Stern, P. H. Gα12/Gα13 subunits of heterotrimeric G proteins mediate parathyroid hormone activation of phospholipase D in UMR-106 osteoblastic cells. Endocrinology 146, 2171–2175 (2005).
Syme, C. A., Friedman, P. A. & Bisello, A. Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling. J. Biol. Chem. 280, 11281–11288 (2005).
Gesty-Palmer, D. et al. Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856–10864 (2006).
Divieti, P., Geller, A. I., Suliman, G., Juppner, H. & Bringhurst, F. R. Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 146, 1863–1870 (2005).
Toribio, R. E. et al. The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J. 24, 1947–1957 (2010).
de Miguel, F. et al. The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracrine stimulation of proliferation in vascular smooth muscle cells. Endocrinology 142, 4096–4105 (2001).
Miao, D. et al. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. Proc. Natl Acad. Sci. USA 105, 20309–20314 (2008).
Bergwitz, C. et al. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. Evidence for a common pattern of ligand–receptor interaction. J. Biol. Chem. 271, 26469–26472 (1996).
Lee, C. et al. Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 135, 1488–1495 (1994).
Gardella, T. J. et al. Determinants of [Arg2]PTH-(1–34) binding and signaling in the transmembrane region of the parathyroid hormone receptor. Endocrinology 135, 1186–1194 (1994).
Luck, M. D., Carter, P. H. & Gardella, T. J. The (1–14) fragment of parathyroid hormone (PTH) activates intact and amino-terminally truncated PTH-1 receptors. Mol. Endocrinol. 13, 670–680 (1999).
Caulfield, M. P. et al. The bovine renal parathyroid hormone (PTH) receptor has equal affinity for two different amino acid sequences: the receptor-binding domains of PTH and PTH-related protein are located within the 14–34 region. Endocrinology 127, 83–87 (1990).
Jüppner, H. et al. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1–34). Endocrinology 134, 879–884 (1994).
Shimizu, M., Carter, P. & Gardella, T. Autoactivation of type 1 parathyroid hormone receptors containing a tethered ligand. J. Biol. Chem. 275, 19456–19460 (2000).
Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J. & Vilardaga, J. P. Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc. Natl Acad. Sci. USA 102, 16084–16089 (2005).
Pioszak, A. A. & Xu, H. E. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc. Natl Acad. Sci. USA 105, 5034–5039 (2008).
Pioszak, A. A., Parker, N. R., Gardella, T. J. & Xu, H. E. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J. Biol. Chem. 284, 28382–28391 (2009).
Siu, F. Y. et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444–449 (2013).
Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438–443 (2013).
Hollenstein, K. et al. Insights into the structure of class B GPCRs. Trends Pharmacol. Sci. 35, 12–22 (2014).
Shimizu, M., Potts, J. J. & Gardella, T. Minimization of parathyroid hormone: novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor. J. Biol. Chem. 275, 21836–21843 (2000).
Goltzman, D., Peytremann, A., Callahan, E., Tregear, G. W. & Potts, J. T. Jr. Analysis of the requirements for parathyroid hormone action in renal membranes with the use of inhibiting analogues. J. Biol. Chem. 250, 3199–3203 (1975).
Doppelt, S. H. et al. Inhibition of the in vivo parathyroid hormone-mediated calcemic response in rats by a synthetic hormone antagonist. Proc. Natl Acad. Sci. USA 83, 7557–7560 (1986).
Chorev, M. et al. Modifications of position 12 in parathyroid hormone and parathyroid hormone related protein: toward the design of highly potent antagonists. Biochemistry 29, 1580–1586 (1990).
Gardella, T. J. et al. Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PThrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137, 3936–3941 (1996).
Bisello, A. et al. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J. Biol. Chem. 277, 38524–38530 (2002).
Takasu, H., Gardella, T. J., Luck, M. D., Potts, J. T. & Bringhurst, F. R. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: implications for design of signal-specific PTH ligands. Biochemistry 38, 13453–13460 (1999).
Gesty-Palmer, D. et al. A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl Med. 1, 1ra1 (2009).
Wisler, J. W., Xiao, K., Thomsen, A. R. & Lefkowitz, R. J. Recent developments in biased agonism. Curr. Opin. Cell Biol. 27, 18–24 (2014).
van der Lee, M. M. et al. β-arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor. Cell Signal. 25, 527–538 (2013).
Mahon, M. J. The parathyroid hormone receptorsome and the potential for therapeutic intervention. Curr. Drug Targets 13, 116–128 (2012).
Mahon, M. J., Donowitz, M., Yun, C. C. & Segre, G. V. Na+/H+ exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 417, 858–861 (2002).
Wang, B. et al. Na/H exchanger regulatory factors control parathyroid hormone receptor signaling by facilitating differential activation of Gα protein subunits. J. Biol. Chem. 285, 26976–26986 (2010).
Ardura, J. A. & Friedman, P. A. Regulation of G protein-coupled receptor function by Na+/H+ exchange regulatory factors. Pharmacol. Rev. 63, 882–900 (2011).
Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373–386 (2010).
Violin, J. D., Crombie, A. L., Soergel, D. G. & Lark, M. W. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol. Sci. 35, 308–316 (2014).
Vilardaga, J. P., Gardella, T. J., Wehbi, V. L. & Feinstein, T. N. Non-canonical signaling of the PTH receptor. Trends Pharmacol. Sci. 33, 423–431 (2012).
Calebiro, D. et al. Persistent cAMP signals triggered by internalized G-protein-coupled receptors. PLoS Biol. 7, e1000172 (2009).
Feinstein, T. N. et al. Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin. J. Biol. Chem. 288, 27849–27860 (2013).
Irannejad, R. et al. Conformational biosensors reveal GPCR signalling from endosomes. Nature 495, 534–538 (2013).
Andreassen, K. V. et al. Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS ONE 9, e92042 (2014).
Luttrell, L. M. Minireview: more than just a hammer: ligand 'bias' and pharmaceutical discovery. Mol. Endocrinol. 28, 281–294 (2014).
Horwitz, M. J., Tedesco, M. B., Gundberg, C., Garcia-Ocana, A. & Stewart, A. F. Short-term, high dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 88, 569–575 (2003).
Horwitz, M. J. et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J. Bone Miner. Res. 20, 1792–1803 (2005).
Horwitz, M. J. et al. A comparison of parathyroid hormone-related protein (1–36) and parathyroid hormone (1–34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J. Bone Miner. Res. 28, 2266–2276 (2013).
Hoare, S. R., Gardella, T. J. & Usdin, T. B. Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor. Effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation. J. Biol. Chem. 276, 7741–7753 (2001).
Dean, T., Vilardaga, J. P., Potts, J. T. Jr & Gardella, T. J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PThrP receptor. Mol. Endocrinol. 22, 156–166 (2008).
Ferrandon, S. et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat. Chem. Biol. 5, 734–742 (2009).
Maeda, A. et al. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc. Natl Acad. Sci. USA 110, 5864–5869 (2013).
Okazaki, M. et al. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc. Natl Acad. Sci. USA 105, 16525–16530 (2008).
Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3, 801–808 (2004).
Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730–739 (2006).
Guo, D., Hillger, J. M., Ijzerman, A. P. & Heitman, L. H. Drug-target residence time—a case for G protein-coupled receptors. Med. Res. Rev. 34, 856–892 (2014).
Gidon, A. et al. Endosomal GPCR signaling turned off by negative feedback actions of PKA and V-ATPase. Nat. Chem. Biol. 10, 707–709 (2014).
Sonawane, N. D., Szoka, F. C. Jr & Verkman, A. S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine–DNA polyplexes. J. Biol. Chem. 278, 44826–44831 (2003).
Hoare, S. R. & Usdin, T. B. Quantitative cell membrane-based radioligand binding assays for parathyroid hormone receptors. J. Pharmacol. Toxicol. Methods 41, 83–90 (1999).
Luttrell, L. M. & Lefkowitz, R. J. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115, 455–465 (2002).
Tsvetanova, N. G. & von Zastrow, M. Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis. Nat. Chem. Biol. 10, 1061–1065 (2014).
Calebiro, D. & Maiellaro, I. cAMP signaling microdomains and their observation by optical methods. Front. Cell. Neurosci. 8, 350 (2014).
Baillie, G. S. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J. 276, 1790–1799 (2009).
Tsvetanova, N. G., Irannejad, R. & von Zastrow, M. G protein-coupled receptor (GPCR) signaling via heterotrimeric G. proteins from endosomes. J. Biol. Chem. 290, 6689–6696 (2015).
Feinstein, T. N. et al. Retromer terminates the generation of cAMP by internalized PTH receptors. Nat. Chem. Biol. 7, 278–284 (2011).
Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609–622 (2009).
Hoffmann, R., Baillie, G. S., MacKenzie, S. J., Yarwood, S. J. & Houslay, M. D. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 18, 893–903 (1999).
Wehbi, V. L. et al. Noncanonical GPCR signaling arising from a PTH receptor–arrestin–Gβγ complex. Proc. Natl Acad. Sci. USA 110, 1530–1535 (2013).
Goldstein, J. L., Brown, M. S., Anderson, R. G., Russell, D. W. & Schneider, W. J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Ann. Rev. Cell Biol. 1, 1–39 (1985).
Vilardaga, J. P., Jean-Alphonse, F. G. & Gardella, T. J. Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 10, 700–706 (2014).
Juppner, H., Schipani, E. & Silve, C. in Principles of Bone Biology, 3rd Edn Vol. 2 (eds Bilezikian, J. P., Raisz, L. G. & Martin, T. J.) 1431–1452 (Elsevier, 2008).
Chen, X. S. et al. Initial characterization of PTH-related protein gene-driven LacZ expression in the mouse. J. Bone Miner. Res. 21, 113–123 (2006).
Lee, K., Deeds, J. D. & Segre, G. V. Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 136, 453–463 (1995).
Juppner, H. et al. A G-protein linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254, 1024–1026 (1991).
Jobert, A. S. et al. Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin. Invest. 102, 34–40 (1998).
Couvineau, A. et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum. Mol. Genet. 17, 2766–2775 (2008).
Risom, L. et al. Identification of six novel PTH1R mutations in families with a history of primary failure of tooth eruption. PLoS ONE 8, e74601 (2013).
Schipani, E., Kruse, K. & Jüppner, H. A constitutively active mutant PTH–PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268, 98–100 (1995).
Schipani, E. et al. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N. Engl. J. Med. 335, 708–714 (1996).
Duchatelet, S., Ostergaard, E., Cortes, D., Lemainque, A. & Julier, C. Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in Eiken and Blomstrand syndromes. Hum. Mol. Genet. 14, 1–5 (2005).
Carter, P. et al. Selective and non-selective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 142, 1534–1545 (2001).
Fraser, W. D. Hyperparathyroidism. Lancet 374, 145–158 (2009).
Stewart, A. F. Clinical practice. Hypercalcemia associated with cancer. N. Engl. J. Med. 352, 373–379 (2005).
Kukreja, S. C. et al. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J. Clin. Invest. 82, 1798–1802 (1988).
Sato, K., Onuma, E., Yocum, R. C. & Ogata, E. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin. Oncol. 30, 167–173 (2003).
Iguchi, H., Aramaki, Y., Maruta, S. & Takiguchi, S. Effects of anti-parathyroid hormone-related protein monoclonal antibody and osteoprotegerin on PTHrP-producing tumor-induced cachexia in nude mice. J. Bone Miner. Metab. 24, 16–19 (2006).
Dresner-Pollak, R. et al. Evaluation in vivo of a potent parathyroid hormone antagonist: [Nle8,18, D-Trp12, Tyr34]bPTH(7–34)Nh2. J. Bone Miner. Res. 11, 1061–1065 (1996).
Rosen, H. N. et al. The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients. Calcif. Tissue Int. 61, 455–459 (1997).
Klopocki, E. et al. Deletion and point mutations of PTHLH cause brachydactyly type E. Am. J. Hum. Genet. 86, 434–439 (2010).
Shoback, D. Clinical Practice. Hypoparathyroidism. N. Engl. J. Med. 359, 391–403 (2008).
Cusano, N. E., Rubin, M. R., Irani, D., Sliney, J. Jr & Bilezikian, J. P. Use of parathyroid hormone in hypoparathyroidism. J. Endocrinol. Invest. 36, 1121–1127 (2013).
Mannstadt, M. et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 1, 275–283 (2013).
Winer, K. K. et al. Synthetic human parathyroid hormone 1–34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97, 391–399 (2012).
Cheloha, R. W., Maeda, A., Dean, T., Gardella, T. J. & Gellman, S. H. Backbone modification of a polypeptide drug alters duration of action in vivo. Nat. Biotechnol. 32, 653–655 (2014).
Kawai, M., Moedder, U. I., Khosla, S. & Rosen, C. J. Emerging therapeutic opportunities for skeletal restoration. Nat. Rev. Drug Discov. 10, 141–156 (2011).
Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).
Miller, P. D. Safety of parathyroid hormone for the treatment of osteoporosis. Curr. Osteoporos. Rep. 6, 12–16 (2008).
Yang, D. et al. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 40, 1453–1461 (2007).
Kraenzlin, M. E. & Meier, C. Parathyroid hormone analogues in the treatment of osteoporosis. Nat. Rev. Endocrinol. 7, 647–656 (2011).
Potts, J. T. & Gardella, T. J. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann. NY Acad. Sci. 1117, 196–208 (2007).
Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007).
Polyzos, S. A., Makras, P., Efstathiadou, Z. & Anastasilakis, A. D. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Exp. Opin. Investigat. Drugs 24, 145–157 (2015).
Horwitz, M. J. et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab. 95, 1279–1287 (2010).
Leder, B. Z. et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, ojennajn bone mineral density in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 100, 697–706 (2015).
Hattersley, G., Dean, T. & Gardella, T. J. Differential binding selectivity of abaloparatide (BA058) compared to PTH and PTHrP type 1 receptor conformations. Endocrine.org [online] (2014).
Acknowledgements
R.W.C. was supported in part by a Biotechnology Training Grant from NIGMS (T32 GM008349). Work in the authors laboratories was supported by NIH grants R01-GM056414 (S.H.G.), RO1-DK087688, R01-DK102495 (J.-P.V.) and P01-DK11794 (T.J.G.).
Author information
Authors and Affiliations
Contributions
All authors researched data for the article, provided substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Cheloha, R., Gellman, S., Vilardaga, JP. et al. PTH receptor-1 signalling—mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 11, 712–724 (2015). https://doi.org/10.1038/nrendo.2015.139
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2015.139
This article is cited by
-
Altered Signaling and Desensitization Responses in PTH1R Mutants Associated with Eiken Syndrome
Communications Biology (2023)
-
Structural details of a Class B GPCR-arrestin complex revealed by genetically encoded crosslinkers in living cells
Nature Communications (2023)
-
Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2
Communications Biology (2022)
-
Precise druggability of the PTH type 1 receptor
Nature Chemical Biology (2022)
-
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis
Nature Reviews Endocrinology (2021)